AR882 is an investigational selective uric acid transporter 1 inhibitor. The Food and Drug Administration (FDA) has granted Fast Track designation to AR882 for the treatment of clinically visible ...
In today's fast-paced lifestyle, problems like joint pain, swelling, and increased uric acid levels have become common, especially among people over the age of 30. One of the main reasons behind this ...
In a phase 2b trial, nearly 100% of patients treated with SAP-001 at the 30mg and 60mg doses achieved the target serum uric acid level of less than 6mg/dL. The Food and Drug Administration (FDA) has ...